{"entity":{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","aka":[],"tldr":"New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease.","summary":"Paul Chapman is a melanoma medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2011 New England Journal of Medicine report of BRIM-3, the phase 3 trial in which the BRAF inhibitor vemurafenib improved overall and progression-free survival compared with dacarbazine in previously untreated BRAF V600E-mutant metastatic melanoma, the first targeted drug to do so in the disease.","asOf":"2026-09-18","links":[],"tags":["melanoma","targeted-therapy","trialist"],"related":[],"cancers":["braf-v600-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-chapman-vemurafenib-nejm-2011"],"journals":[],"dependsOn":[],"notes":[],"role":"Melanoma medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Melanoma","BRAF inhibitors","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chapman%5BAuthor%5D"}],"papers":[]},"route":"/people/paul-chapman/","neighbours":{"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"paper":[{"id":"paper-chapman-vemurafenib-nejm-2011","kind":"paper","name":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation","route":"/key-papers/paper-chapman-vemurafenib-nejm-2011/"}]}}